In Brief: Boehringer Ingelheim
Boehringer Ingelheim: Glaxo Wellcome announces June 9 that B-I has filed an ANDA for form 1 ranitidine. Glaxo's Zantac, the company says, is form 2 ranitidine with patent protection until 2002. Glaxo "is considering all courses of action open to it." Ciba's Geneva generics subsidiary and the Canadian-owned firm Novopharm previously have filed ANDAs for form 1 ranitidine. Glaxo sued both companies...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth